Generation Of Fully Human Monoclonal Antibodies Neutralizing Influenza Virus Use Of SPYMEG As A Novel Human Lymphocyte Fusion Partner

Main Category: Swine Flu
Also Included In: Immune System / Vaccines;  Clinical Trials / Drug Trials;  Pharma Industry / Biotech Industry
Article Date: 27 Jan 2010 - 1:00 PDT

email to a friend   printer friendly   opinions  

Medical & Biological Laboratories Co., Ltd. (MBL), with the collaboration of Osaka University, has successfully generated several fully human monoclonal antibodies against pandemic A (H1N1 and H3N2) type influenza virus by utilizing blood samples from volunteers who were inoculated with influenza vaccine.

Professor Kazuyoshi Ikuta, Ph. D., at the Department of Virology, Research Institute for Microbial Diseases, Osaka University, has confirmed through in vitro experiments that the fully generated human antibodies can neutralize H3N2 influenza virus strains. Professor Ikuta is now evaluating the preventative and therapeutic effects in an infected mouse model. After completing in vivo experiments in infected animal models with the neutralizing antibodies, MBL plans to commence a collaborative clinical development program with a pharmaceutical company. These neutralizing human IgG antibodies against the influenza virus are expected to be effective in severe infections. In combination with anti-viral drugs these antibodies will have greater success than anti-viral drugs alone.

The therapeutic antibodies were generated by using a special cell line, called SPYMEG. This novel cell line is a human lymphocyte fusion partner, it was co-developed by associate professor Naomasa Yamamoto, Ph. D., of Ohu University and MBL. SPYMEG is the cell line established by the cell fusion of MEG-01 with a murine myeloma cell line. Hybridoma cells of human origin are known to be prone to chromosome deletions. The SPYMEG cell line overcomes that problem, resulting in a higher reliability of cell fusion. Utilization of SPYMEG is a simpler and easier way to generate therapeutic monoclonal antibodies than chimerization, or humanization of mouse monoclonal antibodies generated from immunized mice.

At present, MBL is conducting collaborative research to generate neutralizing monoclonal antibodies against swine-origin influenza A (H1N1). MBL is preparing to collaborate with more institutions regarding other infectious viruses.

The fully human monoclonal antibodies against pandemic A (H1N1 and H3N2) type influenza viruses were generated by the utilization of SPYMEG. The antibodies, originated from the blood of a convalescent volunteer recovering from influenza infection or vaccination, are expected to be effective and very safe.

Additionally, the simple principle and wide range of applications of this method may lead to the generation of therapeutic and prophylactic drugs to various infections such as avian influenza A (H5N1).

About MBL

MBL was first established as a Japanese antibody manufacturer in 1969. Since then, the company has been involved in the research, development, manufacture and sale of diagnostic and research reagents.

In the research reagent sector, MBL has been engaged in the worldwide sales of more than 8,000 antibodies that are developed in-house or marketed by foreign and domestic alliance partners. MBL also provides the contract manufacturing of custom-made monoclonal and polyclonal antibodies. MBL has also extended its offering to provide identification kits for mRNA and contract analysis of carbohydrate structure.

In the diagnostic reagent sector, MBL has developed in vitro diagnostic reagents for autoimmune diseases, cancers and aberrant metabolite disorders. As a leader in autoimmune disease diagnostics, MBL's diagnostic products have aided detection of diseases, especially those with poor therapeutic options. MBL also provides an advanced cytopreparation system for the sampling and diagnosis of cervical cancer.

MBL is proud to be an antibody manufacturer with commitment to drug discovery focusing on therapeutic monoclonal antibodies.

About MBL International

MBL International, a subsidiary of MBL, is a leading biotechnology company focused on research, development, production and distribution of research reagents for the life science marketplace worldwide.

MBL International introduces a broad range of innovative antibodies and antibody-related products in the areas of immunology, cancer, autophagy, apoptosis, allergy, fluorescence and other research. Our products include fluorescent protein vectors, kinase assay ELISA kits, monoclonal antibodies, recombinant proteins and the industry's largest selection of G-Protein Coupled Receptor antibodies. MBL International also manufactures and distributes diagnostic ELISA and IF kits in the areas of autoimmune disease, virology and infectious diseases.

In 2008, MBL International increased the company's offering of diagnostic products that are used to test for and diagnose severe skin diseases, viral infections and many additional autoimmune diseases. MBL International is your immune system research provider.

Source: MBL International Corporation

• Additional
• References
• Citations